journal.pone.0247548.pdf 403,24KB
1000 Titel
  • Use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers associated with lower risk of COVID-19 in household contacts
1000 Autor/in
  1. Armstrong, Katrina |
  2. Soltoff, Alexander |
  3. Rieu-Werden, Meghan |
  4. Metlay, Joshua |
  5. Haas, Jennifer |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-03-02
1000 Erschienen in
1000 Quellenangabe
  • 16(3):e0247548
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • |
1000 Ergänzendes Material
  • |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • BACKGROUND: Use of angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) has been hypothesized to affect COVID-19 risk. OBJECTIVE: To examine the association between use of ACEI/ARB and household transmission of COVID-19. METHODS: We conducted a modified cohort study of household contacts of patients who tested positive for COVID-19 between March 4 and May 17, 2020 in a large Northeast US health system. Household members were identified by geocoding and full address matching with exclusion of addresses with >10 matched residents or known congregate living functions. Medication use, clinical conditions and sociodemographic characteristics were obtained from electronic medical record (EMR) data on cohort entry. Cohort members were followed for at least one month after exposure to determine who tested positive for SARS-CoV-2. Mixed effects logistic regression and propensity score analyses were used to assess adjusted associations between medication use and testing positive. RESULTS: 1,499 of the 9,101 household contacts were taking an ACEI or an ARB. Probability of COVID-19 diagnosis during the study period was slightly higher among ACEI/ARB users in unadjusted analyses. However, ACEI/ARB users were older and more likely to have clinical comorbidities so that use of ACEI/ARB was associated with a decreased risk of being diagnosed with COVID-19 in mixed effect models (OR 0.60, 95% CI 0.44–0.81) or propensity score analyses (predicted probability 18.6% in ACEI/ARB users vs. 24.5% in non-users, p = 0.03). These associations were similar within age and comorbidity subgroups, including patients with documented hypertension, diabetes or cardiovascular disease, as well as when including other medications in the models. CONCLUSIONS: In this observational study of household transmission, use of ACEIs or ARBs was associated with a decreased risk of being diagnosed with COVID-19. While causality cannot be inferred from these observational data, our results support current recommendations to continue ACEI/ARB in individuals at risk of COVID-19 exposure.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal Immunology
lokal Medical risk factors
lokal Diabetes mellitus
lokal Virus testing
lokal Cardiovascular disease risk
lokal Asthma
lokal SARS-CoV-2
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
1000 Label
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6425904.rdf
1000 Erstellt am 2021-03-03T08:31:40.333+0100
1000 Erstellt von 122
1000 beschreibt frl:6425904
1000 Bearbeitet von 122
1000 Zuletzt bearbeitet Wed Mar 03 08:32:53 CET 2021
1000 Objekt bearb. Wed Mar 03 08:32:31 CET 2021
1000 Vgl. frl:6425904
1000 Oai Id
  1. |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source